Study Evaluating Etanercept in Moderate to Severe Asthma

Wyeth

Status and phase: Completed; Phase 2

Conditions: Asthma

Treatments: Drug: Etanercept

Study type: Interventional

Funder types: Industry

Identifiers

NCT00141791

0881A8-205

Details and patient eligibility

About

The primary objective of the study is to assess the efficacy and safety of etanercept 25 mg given twice weekly in subjects with moderate to severe persistent asthma.

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Moderate to severe persistent asthma for at least 1 year
• Demonstrated reversibility of at least 9% and (FEV1) 50% to 80% predicted
• Subjects must be on a high-dose inhaled corticosteroid (ICS)

Exclusion criteria

• Previous treatment with etanercept
• Current use of cigarettes
• Significant concurrent medical conditions at the time of screening

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind